TABLE 3.
Comparison of demographic variables at baseline and after GMA therapy between patients who achieved clinical remission and those who did not following a course of GMA therapy
| Variable | Before GMA | After GMA | ||||
|---|---|---|---|---|---|---|
| Clinical remission group (n = 38) | Non‐remission group (n = 10) | P value | Clinical remission group (n = 38) | Nonremission group (n = 10) | P value | |
| Age, year | 45.47 ± 16.26 | 49.50 ± 11.30 | .31 | ‐ | ‐ | ‐ |
| Duration of UC, month | 41.24 ± 59.55 | 54.80 ± 88.42 | .57 | ‐ | ‐ | ‐ |
| ESR (mm/h) | 19.84 ± 13.46 | 33.2 ± 20.30 | .15 | 15.69 ± 12.08 | 23.9 ± 21.37 | .12 |
| WBC (1000/μL) | 7.10 ± 2.53 | 6.99 ± 1.87 | .90 | 6.35 ± 2.65 | 6.02 ± 2.04 | .72 |
| Hb (g/dL) | 12.90 ± 1.52 | 10.38 ± 2.70 | .00* | 12.48 ± 1.43 | 10.29 ± 2.21 | .01* |
| PLT (10 000/μL) | 28.61 ± 8.09 | 34.52 ± 19.16 | .14 | 26.31 ± 8.92 | 25.12 ± 9.51 | .71 |
| IL‐6 (pg/mL) | 27.81 ± 34.56 | 28.05 ± 16.16 | .99 | 23.55 ± 25.64 | 43.24 ± 24.01 | .12 |
| IL‐8 (pg/mL) | 504.94 ± 739.60 | 665.00 ± 608.44 | .62 | 528.60 ± 522.41 | 703.80 ± 721.16 | .52 |
| TNF‐α (pg/mL) | 84.78 ± 88.47 | 60.32 ± 54.27 | .52 | 75.35 ± 60.27 | 102.26 ± 80.40 | .39 |
| Albumin (g/L) | 41.12 ± 4.97 | 33.96 ± 4.67 | .00* | 40.25 ± 4.19 | 33.42 ± 4.83 | .00* |
| CAI | 6.84 ± 1.82 | 10.40 ± 3.63 | .04* | 1.66 ± 1.05 | 7.60 ± 2.32 | .00* |
| Mayo‐SE | 2.39 ± 0.55 | 2.40 ± 0.52 | .226 | 1.33 ± 0.73 | 2.6 ± 0.55 | .01* |
*
P < .05.
Note. Data are presented as the mean ± SD values, compared by one‐way analysis of variance statistic.
Abbreviations: CAI, clinical activity index; ESR, erythrocyte sedimentation rate; HB, haemoglobin; IL, interleukin; PLT, platelet; UC, ulcerative colitis; WBC, white blood cell.